Log in

Tcr2 Therapeutics News Headlines (NASDAQ:TCRR)

$13.96
-0.72 (-4.90 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$13.77
Now: $13.96
$14.70
50-Day Range
$12.95
MA: $14.64
$16.01
52-Week Range
$10.04
Now: $13.96
$25.47
Volume42,147 shs
Average Volume61,687 shs
Market Capitalization$335.46 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Tcr2 Therapeutics (NASDAQ TCRR) News Headlines

Source:
DateHeadline
-$0.65 Earnings Per Share Expected for Tcr2 Therapeutics Inc (NASDAQ:TCRR) This Quarter-$0.65 Earnings Per Share Expected for Tcr2 Therapeutics Inc (NASDAQ:TCRR) This Quarter
www.americanbankingnews.com - February 21 at 11:46 AM
Tcr2 Therapeutics (NASDAQ:TCRR) and Repligen (NASDAQ:RGEN) Financial AnalysisTcr2 Therapeutics (NASDAQ:TCRR) and Repligen (NASDAQ:RGEN) Financial Analysis
www.americanbankingnews.com - February 19 at 10:37 PM
TCR² Therapeutics to Participate in Two Upcoming Conferences in FebruaryTCR² Therapeutics to Participate in Two Upcoming Conferences in February
finance.yahoo.com - February 18 at 7:14 AM
Tcr2 Therapeutics Inc (NASDAQ:TCRR) Receives Average Rating of "Buy" from BrokeragesTcr2 Therapeutics Inc (NASDAQ:TCRR) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 13 at 3:58 AM
Head-To-Head Review: BioCryst Pharmaceuticals (NASDAQ:BCRX) vs. Tcr2 Therapeutics (NASDAQ:TCRR)Head-To-Head Review: BioCryst Pharmaceuticals (NASDAQ:BCRX) vs. Tcr2 Therapeutics (NASDAQ:TCRR)
www.americanbankingnews.com - February 7 at 12:06 AM
TCR² Therapeutics to Present an Allogeneic Construct at the Keystone Symposia Conference on Emerging Cellular Therapies: Cancer and BeyondTCR² Therapeutics to Present an Allogeneic Construct at the Keystone Symposia Conference on Emerging Cellular Therapies: Cancer and Beyond
finance.yahoo.com - February 3 at 9:22 AM
Tcr2 Therapeutics Inc (NASDAQ:TCRR) Expected to Announce Earnings of -$0.65 Per ShareTcr2 Therapeutics Inc (NASDAQ:TCRR) Expected to Announce Earnings of -$0.65 Per Share
www.americanbankingnews.com - January 29 at 9:42 PM
Need To Know: TCR2 Therapeutics Inc. (NASDAQ:TCRR) Insiders Have Been Buying SharesNeed To Know: TCR2 Therapeutics Inc. (NASDAQ:TCRR) Insiders Have Been Buying Shares
finance.yahoo.com - January 21 at 6:06 PM
Tcr2 Therapeutics (TCRR) Presents At 38th Annual J.P. Morgan Healthcare Conference - SlideshowTcr2 Therapeutics (TCRR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 17 at 5:55 PM
TCR(2) Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferenceTCR(2) Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
www.marketwatch.com - January 7 at 5:00 PM
TCR² Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferenceTCR² Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 7:06 AM
TCR² Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateTCR² Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - November 12 at 11:54 AM
TCRR TCR2 Therapeutics Inc. Common StockTCRR TCR2 Therapeutics Inc. Common Stock
www.nasdaq.com - October 24 at 7:14 AM
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth PlansTCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - October 23 at 2:18 PM
Tcr² Therapeutics Appoints Industry Veteran Angela Justice, Ph.D., as Chief People OfficerTcr² Therapeutics Appoints Industry Veteran Angela Justice, Ph.D., as Chief People Officer
finance.yahoo.com - October 9 at 7:46 AM
TCR² Therapeutics to Present at the Cantor Global Healthcare ConferenceTCR² Therapeutics to Present at the Cantor Global Healthcare Conference
finance.yahoo.com - September 27 at 1:05 PM
TCR2 Therapeutics Sees Hammer Chart Pattern: Time to Buy?TCR2 Therapeutics Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - September 3 at 12:40 PM
TCR² Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry ConferenceTCR² Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference
finance.yahoo.com - August 30 at 11:52 AM
How Much Of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Do Institutions Own?How Much Of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Do Institutions Own?
finance.yahoo.com - August 22 at 3:46 PM
TCR2 Therapeutics Inc. (TCRR) Shares March Higher, Can It Continue?TCR2 Therapeutics Inc. (TCRR) Shares March Higher, Can It Continue?
finance.yahoo.com - August 22 at 11:35 AM
TCR2 Therapeutics EPS beats by $0.03TCR2 Therapeutics EPS beats by $0.03
seekingalpha.com - August 8 at 12:50 PM
TCR² Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateTCR² Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - August 8 at 12:50 PM
TCR² Therapeutics to Participate in Upcoming Conferences in AugustTCR² Therapeutics to Participate in Upcoming Conferences in August
finance.yahoo.com - August 6 at 8:38 PM
TCR2 Therapeutics Deepens Manufacturing and Immuno-Oncology Expertise with Key HiresTCR2 Therapeutics Deepens Manufacturing and Immuno-Oncology Expertise with Key Hires
finance.yahoo.com - August 6 at 12:41 PM
TCR2 Therapeutics teams up with NCI in cancer study of proprietary T cells; shares up 3%TCR2 Therapeutics teams up with NCI in cancer study of proprietary T cells; shares up 3%
seekingalpha.com - July 31 at 1:44 PM
TCR2 Therapeutics Announces Partnership with the National Cancer Institute for Phase 1/2 Trial of TC-210TCR2 Therapeutics Announces Partnership with the National Cancer Institute for Phase 1/2 Trial of TC-210
finance.yahoo.com - July 31 at 1:44 PM
TCR2 Therapeutics Added to Russell 2000®, 3000® and Microcap® IndexesTCR2 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
finance.yahoo.com - June 28 at 9:25 AM
Who Has Been Buying TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?Who Has Been Buying TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
finance.yahoo.com - May 24 at 3:26 PM
TCR2 Therapeutics Inc. (TCRR) Q1 2019 Earnings Call TranscriptTCR2 Therapeutics Inc. (TCRR) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 15 at 5:58 AM
TCR2 Therapeutics (TCRR) CEO Garry Menzel on Q1 2019 Results - Earnings Call TranscriptTCR2 Therapeutics' (TCRR) CEO Garry Menzel on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 8:26 PM
TCR2 Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate UpdateTCR2 Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - May 13 at 8:26 PM
TCR2 Therapeutics Publishes First Peer-Reviewed Data Demonstrating Superior Anti-Tumor Activity of the Company’s Novel TRuC™-T CellsTCR2 Therapeutics Publishes First Peer-Reviewed Data Demonstrating Superior Anti-Tumor Activity of the Company’s Novel TRuC™-T Cells
finance.yahoo.com - May 7 at 7:45 AM
TCR2 Therapeutics Announces First Quarter 2019 Earnings Conference Call and WebcastTCR2 Therapeutics Announces First Quarter 2019 Earnings Conference Call and Webcast
finance.yahoo.com - April 30 at 7:32 AM
TCR2 Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate UpdateTCR2 Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - April 1 at 3:19 PM
TCR2 Therapeutics Presents Preclinical Data on its Lead Solid Tumor and Blood Cancer Programs at the American Association for Cancer Research (AACR) Annual MeetingTCR2 Therapeutics Presents Preclinical Data on its Lead Solid Tumor and Blood Cancer Programs at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - March 28 at 3:22 PM
TCR2 collaborates with CGT Catapult to manufacture T cell therapies for cancerTCR2 collaborates with CGT Catapult to manufacture T cell therapies for cancer
seekingalpha.com - March 26 at 3:20 PM
TCR2 Therapeutics Announces Collaboration With Cell and Gene Therapy Catapult for the Manufacturing of its Novel T Cell Therapies for CancerTCR2 Therapeutics Announces Collaboration With Cell and Gene Therapy Catapult for the Manufacturing of its Novel T Cell Therapies for Cancer
finance.yahoo.com - March 26 at 3:20 PM
TCR2 Therapeutics Inc.TCR2 Therapeutics Inc.
www.barrons.com - March 4 at 3:15 PM
TCR2 Therapeutics Announces Exercise of Over-Allotment OptionTCR2 Therapeutics Announces Exercise of Over-Allotment Option
finance.yahoo.com - February 27 at 5:17 AM
IPO Outlook For The Week: Biotechs And Another Virgin Group AdditionIPO Outlook For The Week: Biotechs And Another Virgin Group Addition
finance.yahoo.com - February 26 at 3:15 PM
TCR2 Therapeutics Announces Pricing of Initial Public Offering of Common StockTCR2 Therapeutics Announces Pricing of Initial Public Offering of Common Stock
finance.yahoo.com - February 26 at 3:15 PM
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel